Views on Amyloid Hypothesis and Secretase Inhibitors for Treating Alzheimers Disease: Progress and Problems

Author(s): Jeffrey-Tri Nguyen, Abdellah Yamani, Yoshiaki Kiso

Journal Name: Current Pharmaceutical Design

Volume 12 , Issue 33 , 2006

Become EABM
Become Reviewer
Call for Editor


Alzheimers disease is a form of sporadic, age-related dementia. According to the “amyloid hypothesis”, the processing of β-amyloid precursor protein (APP) leads to the formation of senile plaque aggregates which subsequently congest normal neurological functions. Currently, prophylaxis is testimonial, while treatment relies mainly on symptomatic relief. This review emphasizes the importance of disrupting the pathological processing of APP via α-secretase activators, β- and γ-secretase inhibitors, and compounds that bind APP. The style of writing should appeal to those with strong interests in medicinal chemistry with an equal balance of medicine and chemistry.

Keywords: Alzheimer's disease, amyloid peptide, drug development, inhibitor, secretase

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [4295 - 4312]
Pages: 18
DOI: 10.2174/138161206778792976
Price: $65

Article Metrics

PDF: 5